ArticleMolecules (Basel, Switzerland)2026
The Preparation and Photophysical Properties of 3-Substituted 4-Azafluorenones.
Article in Molecules (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
A method for the preparation of 3-substituted azafluorenones is presented. Condensation of ninhydrin with thiomethylamidrazone gives a triazine from which 3-thiomethyl-4-azafluorenone is produced after Diels-Alder cycloaddition with norbornadiene followed by two retro-Diels-Alder cycloreversions. Oxidation of the sulfide to the sulfone allows for nucleophilic substitution at the 3-position. Using different amidrazones can give other substituents at the 3-position directly. The photophysical properties of the azafluorenones are characterized and compared with computational calculations. Compounds with a substituent bearing an n-donor group show significant fluorescence. The n-donor group is prominent in the HOMOs in these systems, whereas in the compounds with weak emission, it is not. The El Sayed rules for intersystem crossing do not explain the emission intensity ordering of these compounds.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.